Since Rinri’s lead product candidate, Rincell-1, aims to regenerate auditory neurons, individuals with presbycusis or Auditory Neuropathy will be treated first, as these conditions are are associated with the loss and/or dysfunction of auditory neurons.

While initially focusing on patients with auditory neuron-related hearing loss, we will continue to consider a broad range of aetiologies and populations to better understand the individuals our therapeutic candidate may treat.